GENEVA, July 18 -- SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. filed a patent application (CN2026/071621) for “ANTI-CLDN6 ANTIBODY DRUG CONJUGATE AND USE THEREOF”. With publication no. WO/2026/149528, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 47/68
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....